Central nervous system (CNS) tumors are resistant to nitrosoureas and related alkylating agents because of upregulation of O6-alkylguanine-DNA alkyltransferase (AGT), which repairs the cytotoxic alkyl lesions at the 6-position of guanine in DNA. CNS tumors can be sensitized to alkylating drugs by pre-treatment with O6-benzylguanine (BG), a compound that inactivates AGT. Unfortunately, chemical depletion of AGT in animals and tissues produces indiscriminate depletion of AGT in both normal and tumor tissue, which increases normal tissue toxicity and limits the dose of the alkylating drug that can be used. The applicant has accomplished downregulation of AGT and its signal (mRNA) in cultures and xenografts of human CNS neoplasms by restricting methionine and replacing it with homocystine, which is effectively converted to methionine by normal tissue but not by methionine-dependent tumors. Depletion of methionine in animals with a combination of a methionine/choline deficient diet and exogenous administrations of methioninase results in tumor stasis in methionine-dependent tumors without toxicity to normal tissue, if homocystine is administered systemically at the same time. However, tumor growth resumes when treatment is discontinued. During the period of stasis and growth arrest in the tumors, their AGT activity is substantially reduced, making the tumors more sensitive to alkylating drugs without increasing toxicity to normal tissue. In this application, the applicant seeks to improve the efficiency of reduction in plasma methionine by a combination of dietary and pharmacologic means (Aim 1), correlate the depletion of methionine with AGT reduction in a variety of xenografts with variable sensitivity to methionine depletion (Aim 2), document the enhanced efficacy of treatment with alkylating drugs in methionine depleted tumors (Aim 3), and verify that there is no unacceptable normal tissue toxicity from this regimen (Aim 4). The applicant's long-term objective is to identify and develop new and effective forms of therapy for human CNS tumors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA078561-03
Application #
6174151
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Forry-Schaudies, Suzanne L
Project Start
1998-07-01
Project End
2001-05-31
Budget Start
2000-07-01
Budget End
2001-05-31
Support Year
3
Fiscal Year
2000
Total Cost
$78,268
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Neurology
Type
Schools of Medicine
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Kokkinakis, Demetrius M; Brickner, Anthony G; Kirkwood, John M et al. (2006) Mitotic arrest, apoptosis, and sensitization to chemotherapy of melanomas by methionine deprivation stress. Mol Cancer Res 4:575-89
Kokkinakis, Demetrius M; Ahmed, Mansoor M; Chendil, Damodaran et al. (2003) Sensitization of pancreatic tumor xenografts to carmustine and temozolomide by inactivation of their O6-Methylguanine-DNA methyltransferase with O6-benzylguanine or O6-benzyl-2'-deoxyguanosine. Clin Cancer Res 9:3801-7
Kokkinakis, Demetrius M; Wick, Jacquellyn B; Zhou, Qing Xian (2002) Metabolic response of normal and malignant tissue to acute and chronic methionine stress in athymic mice bearing human glial tumor xenografts. Chem Res Toxicol 15:1472-9
Bocangel, Dora B; Finkelstein, Sydney; Schold, S Clifford et al. (2002) Multifaceted resistance of gliomas to temozolomide. Clin Cancer Res 8:2725-34
Kokkinakis, D M; Watson, M L; Honig, L S et al. (2001) Characterization of initiated cells in N-methylnitrosourea-induced carcinogenesis of the CNS in the adult rat. Neuro Oncol 3:99-112
Kokkinakis, D M; Hoffman, R M; Frenkel, E P et al. (2001) Synergy between methionine stress and chemotherapy in the treatment of brain tumor xenografts in athymic mice. Cancer Res 61:4017-23
Kokkinakis, D M; Bocangel, D B; Schold, S C et al. (2001) Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide. Clin Cancer Res 7:421-8
Kokkinakis, D M; Moschel, R C; Pegg, A E et al. (2000) Potentiation of BCNU antitumor efficacy by 9-substituted O6-benzylguanines. Effect of metabolism. Cancer Chemother Pharmacol 45:69-77
Kokkinakis, D M; Moschel, R C; Pegg, A E et al. (1999) Eradication of human medulloblastoma tumor xenografts with a combination of O6-benzyl-2'-deoxyguanosine and 1,3-bis(2-chloroethyl)1-nitrosourea. Clin Cancer Res 5:3676-81